Navigation Links
iCardiac's Highly Automated QT(sm) Technology Cross-Validated Against Results from Five Leading ECG Core Laboratories
Date:5/11/2009

Results Based on FDA's ECG Data Warehouse and Shared at 2009 Drug Information Association Conference

Rochester, NY (PRWEB) May 11, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development, today announced that the company's Highly Automated QT technology has now been validated against manual or semi-automated measurements made by five leading ECG core laboratories. The data for the analysis comprised a total of six independent Thorough QT (TQT) studies stored in FDA's ECG warehouse. The results of the validation study found the measurements made by Highly Automated QT to be statistically consistent with the measurements made independently and in a blinded fashion by the core laboratories.

"This is an important step for cardiac safety testing," said Sasha Latypova, Executive Vice President at iCardiac. "Given these results, pharmaceutical companies can be confident in using the Highly Automated QT technology in their cardiac safety studies to increase the robustness of their study results, as well as to drive cost reductions in their development process."

The Highly Automated QT technology, which iCardiac has licensed from the University of Rochester, is unique in the industry because it combines advanced ECG signal processing with a quality assurance process involving cardiologists. With this approach, only a small portion of the entire Thorough QT (TQT) dataset requires manual over-reading, thereby generating significant cost and time savings to sponsors while at the same time providing assurance to the regulators regarding data quality.

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision and high cost of the "gold standard" manual QT measurements has lead to efforts toward automating QT interval measurement.

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/automatedQT/corelabs/prweb2394714.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. iCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT Studies
2. VARI researcher chosen for highly competitive Scholar-in-Training Award
3. Dr.Khanna Featured in Highly Respected Trade Journal
4. Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients
5. A New, Highly Effective, Non-Narcotic Pain Medication Now Available for Chronic Pain Patients
6. Perlabella Introduces a Highly Concentrated and Affordable Anti-Aging Skin Care Line
7. Yankees Will Become First MLB Team to Integrate Highly Advanced Antimicrobial System
8. Specialists are Highly Satisfied with the Safety and Efficacy of Atripla and Isentress in the Treatment of HIV Patients
9. Pennsylvania Health Department Offers Tips to Prevent Spread of Highly Contagious Norovirus
10. Choosing a Highly-Trained Bariatric Surgeon Crucial as Surgical Weight Loss Procedures Rise and Less-Qualified Doctors Flood the Market
11. Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with the ... study from the Osteoarthritis Initiative shows that certain people who experience consistent ... in advance may give doctors the opportunity to treat patients before the problem becomes ...
(Date:5/26/2017)... Texas (PRWEB) , ... May 26, 2017 , ... Amir ... Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS ... , “We are pleased to be the first in Arkansas to introduce the most ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional Budget Office ... U.S. House on May 4, would result in 23 million Americans losing their health ... the 2010 Patient Protection and Affordable Care Act (ACA). , “It is clear ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon ... informational blog post on insurance options. If a Bay Area patient has to search ... time and money. Visiting an in-network provider for a second opinion can ensure a ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: the ... others. “Cactus Jack: Against All Odds” is the creation of published author, Walter ... is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane have ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" Fortuna ... be the first to eliminate the need for embryonic and ... to treat neurodegenerative diseases. Fortuna announced ... Professor Michael Fehlings , MD, PhD; Father Kevin ... MD, MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)... , May 4, 2017 Clarius ... its wireless, handheld ultrasound scanners this week at ... Scientific Meeting (ACOG) in San Diego, ... "Clarius is the perfect tool for ... and heart rate, and evaluate pregnancy-related complications like ...
(Date:5/4/2017)... 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it is teaming up ... Technologies Limited to lower diabetes healthcare costs in ... card, which is available throughout all provinces and territories ... be eligible for additional savings when shopping for Dario ...
Breaking Medicine Technology: